23andme glp-1 As a medical school professor, I get asked why drugs work miracles for some and barely budge for others. A new Nature paper from gives part of the answer: your Genetic predictors for GLP-1 weight

In the 2026 survey 73.9% (249/337 [95% CIs 69.0-78.4%]) of patients who are eligible for a GLP-1RA who have not used these a GLP-1RA and have expressed an interest in participating in a clinical trial of a GLP-1RA

Get essential vitamins and minerals to help fill nutritional gaps while on your GLP-1 weight loss journey.

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

The weight loss market is undergoing a seismic shift as the focus moves from injectable peptides to oral small molecule GLP-1 receptor agonists, led by Eli Lillys promising candidate, orforglipron

Effects of Combined Interventions of Exercise and Diet or Exercise and Supplementation on Breast Cancer Patients: A Systematic Review

Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis